Oxcarbazepine Suspension
Product Images NDC 65162-649

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 65162-649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

9f14a9c2-figure-01 (Oxcarbazepine Oral Suspension Usp 1)

FDA Label Image

Oxcarbazepine Oral Suspension Usp 10

FDA Label Image

Oxcarbazepine Oral Suspension Usp 11

FDA Label Image

Oxcarbazepine Oral Suspension Usp 12

FDA Label Image

Oxcarbazepine Oral Suspension Usp 13

FDA Label Image

Oxcarbazepine Oral Suspension Usp 14

This is a description for a medication called Oxcarbazepine which is in the form of oral suspension. Each 5mL of the medicine contains 300mg of NDC 65162-649-78 bazepine. The medication comes in a container that should be stored at 20-25°C and should be kept away from children. The medication guide is provided separately and should be read before use. The brand name is Doty Amneal Pharmaceuticals LLC.*

FDA Label Image

Oxcarbazepine Oral Suspension Usp 15

This is a label of a 300 mg/5mL Oxcarbazepine oral suspension. The label mentions the drug components and the appropriate dosage information. It also provides instructions on storage and usage. A pharmacist should disperse the medication, and the medication guide is provided separately. The product should be used within seven weeks of the opening of the bottle.*

FDA Label Image

9f14a9c2-figure-02 (Oxcarbazepine Oral Suspension Usp 2)

FDA Label Image

9f14a9c2-figure-03 (Oxcarbazepine Oral Suspension Usp 3)

This appears to be a statistical analysis report using log-rank test to compare the effect of Oxcarbazeping treatment versus Placebo in reducing the incidence of seizures. The data shows a p-value of 0.045, which is considered statistically significant. The table suggests that the observations were recorded over a period of 140 days, and the graph displays the progress of the treatment groups over time.*

FDA Label Image

9f14a9c2-figure-04 (Oxcarbazepine Oral Suspension Usp 4)

FDA Label Image

9f14a9c2-figure-05 (Oxcarbazepine Oral Suspension Usp 5)

The text describes the results of a statistical test called the "log-rank test". The test resulted in a p-value of 0.0001. Additionally, there is a graph displaying "Time to exit" in days with markers at every 10 days up to 130 days. There are two treatment groups labeled "HIGH" and "LOW". A portion of the text after the graph appears to be corrupted, so it is not clear what it describes.*

FDA Label Image

250 mL (Oxcarbazepine Oral Suspension Usp 6)

FDA Label Image

250 50 mL (Oxcarbazepine Oral Suspension Usp 7)

FDA Label Image

Oxcarbazepine Oral Suspension Usp 8

FDA Label Image

Oxcarbazepine Oral Suspension Usp 9

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.